ICU vs. FEMY, NXGL, RVP, NRXS, ALUR, PETV, CLGN, NXL, IRIX, and XAIR
Should you be buying SeaStar Medical stock or one of its competitors? The main competitors of SeaStar Medical include Femasys (FEMY), NexGel (NXGL), Retractable Technologies (RVP), NeurAxis (NRXS), Allurion Technologies (ALUR), PetVivo (PETV), CollPlant Biotechnologies (CLGN), Nexalin Technology (NXL), IRIDEX (IRIX), and Beyond Air (XAIR). These companies are all part of the "medical equipment" industry.
SeaStar Medical vs. Its Competitors
SeaStar Medical (NASDAQ:ICU) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.
Femasys has higher revenue and earnings than SeaStar Medical. Femasys is trading at a lower price-to-earnings ratio than SeaStar Medical, indicating that it is currently the more affordable of the two stocks.
SeaStar Medical has a beta of -1.09, meaning that its stock price is 209% less volatile than the S&P 500. Comparatively, Femasys has a beta of -2.56, meaning that its stock price is 356% less volatile than the S&P 500.
SeaStar Medical has a net margin of 0.00% compared to Femasys' net margin of -1,242.06%. SeaStar Medical's return on equity of 0.00% beat Femasys' return on equity.
Femasys has a consensus price target of $8.67, suggesting a potential upside of 842.03%. Given Femasys' stronger consensus rating and higher probable upside, analysts plainly believe Femasys is more favorable than SeaStar Medical.
In the previous week, SeaStar Medical had 7 more articles in the media than Femasys. MarketBeat recorded 9 mentions for SeaStar Medical and 2 mentions for Femasys. Femasys' average media sentiment score of 0.93 beat SeaStar Medical's score of -0.01 indicating that Femasys is being referred to more favorably in the news media.
1.7% of SeaStar Medical shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 1.3% of SeaStar Medical shares are owned by company insiders. Comparatively, 11.5% of Femasys shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Femasys beats SeaStar Medical on 10 of the 16 factors compared between the two stocks.
Get SeaStar Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICU and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ICU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SeaStar Medical Competitors List
Related Companies and Tools
This page (NASDAQ:ICU) was last updated on 7/16/2025 by MarketBeat.com Staff
